Form 4: Akero Therapeutics CTO Acquires Shares Through Employee Stock Purchase Plan

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, acquired 299 shares of common stock at a discounted price through the company's Employee Stock Purchase Plan.

Summary

• Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics, Inc. (AKRO), acquired 299 shares of common stock.
• The transaction occurred on June 30, 2025.
• Shares were purchased at a price of $23.868 per share.
• The acquisition was made pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
• The purchase price represents 85% of the closing price of Akero Therapeutics' common stock on January 2, 2025.
• Following this transaction, Mr. Gangloff beneficially owns 23,751 shares of common stock.
• The transaction is exempt under SEC Rules 16b-3(c) and 16b-3(d).

Sentiment

Score: 7

Explanation: The acquisition of shares by a Chief Technology Officer, even through a routine ESPP, generally indicates a positive alignment of interests and confidence in the company's future prospects, especially given the discounted purchase price.

Positives

• An executive, the Chief Technology Officer, is acquiring shares, which can be seen as a sign of confidence in the company's future.
• The shares were acquired at a discounted price of $23.868, representing 85% of the closing price on January 2, 2025, indicating a favorable purchase for the insider.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction under an Employee Stock Purchase Plan, which is a common benefit offered by publicly traded companies across various industries to encourage employee ownership and align interests with shareholders. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The acquisition of shares by a key executive may be viewed positively as it aligns management's interests with those of shareholders, potentially signaling confidence in the company's long-term value.
• Employees: The transaction highlights the existence and utilization of an Employee Stock Purchase Plan, which is a benefit that can incentivize employee retention and performance by offering discounted share purchases.

Key Dates

Recommendation

Keywords

Akero Therapeutics, AKRO, Scott A. Gangloff, Chief Technology Officer, CTO, Insider Trading, Form 4, SEC Filing, Stock Purchase, Employee Stock Purchase Plan, ESPP, Equity Acquisition